The findings come from sub-analysis of a study into the benefits of ARBs in patients with coronary artery disease (CAD).
This showed that the risk of major adverse cardiac events was reduced by 21 per cent in patients with impaired renal function.
ARBs also reduced the risk of new-onset diabetes by 63 per cent, delegates were told at the American Heart Association scientific sessions in Orlando, Florida.
For the study, over 2,000 patients with CAD were randomly assigned to treatment with the ARB candesartan or standard therapy.
In Japan this is a calcium-channel blocker or beta-blocker, followed by a diuretic. However, 71 per cent of these patients were also taking ACE inhibitor, said lead researcher Dr Hiroshi Kasanuki from Tokyo Women’s Medical University.
The study showed that ARBs had little effect on the risk of major adverse cardiac events in these patients at four-year follow-up, reducing risk by a non-significant 11 per cent.
rachel.liddle@haymarket.com
For more details visit the Scientific Sessions 2007 website
Comment below and tell us what you think
